3-(((2-Guanidinothiazol-4-yl)methyl)thio)-N-sulfamoylpropanamide

Catalog No. :
ACUIGE032
CAS No. :
106433-44-7
Molecular Formula :
C8H14N6O3S3
Molecular Weight :
338.44

IUPAC Name:Famotidine sulfamoyl propanamide

3-(((2-Guanidinothiazol-4-yl)methyl)thio)-N-sulfamoylpropanamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-(((2-Guanidinothiazol-4-yl)methyl)thio)-N-sulfamoylpropanamide
IUPAC NameFamotidine sulfamoyl propanamide
Molecular FormulaC8H14N6O3S3
Molecular Weight338.44
SMILESO=C(NS(=O)(N)=O)CCSCC1=CSC(NC(N)=N)=N1
InChI KeyBPCROVNHEMFQOD-UHFFFAOYSA-N
Synonym3-[[[2-[(Aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]-N-(aminosulfonyl)propanamide;[3-[[[2-(Diaminomethyleneamino)-4-thiazolyl]methyl]thio]propionyl]sulfamide (Famotidine Impurity);Famotidine Impurity C(EP);Propanamide, 3-[[[2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]-N-(aminosulfonyl)-;Famotidine Related Compound-C / Famotidine EP Impurity-C (Free base);Famotidine sulfamoyl propanamide;Famotidine Impurity C (RS) as HCl salt: 3-[[[2-[(diaminomethylene)amino]thiazol-4- yl]methyl]sulphanyl]-N-sulphamoylpropanamide Hydrochloride
CAS No.106433-44-7

Synthetic Route by SureRoute

1. ACUIGE032 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACBDCN108 route compound structure diagram
    ACBDCN1087803-58-9 In Stock
  4. Then
  5. ACUIGE032 route product structure diagram
    ACUIGE032106433-44-7
Inquiry

2. ACUIGE032 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACUIGE032 route product structure diagram
    ACUIGE032106433-44-7
Inquiry

Comments (0)